AllianzIM U.S. Large Cap Buffer10 Apr ETF APRT 深 滬
等待開盤 10-28 09:30:00 美东时间
41.0343
+0.081
+0.20%
華盛通- 最 高41.035
- 今 開41.01
- 成交量 2548股
- 最 低 41.005
- 昨 收 40.9532
- 總市值 4616.36万
- 52周最高 41.035
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 33.465
- 委 比 -33.33%
- 總股本 112.50万
- 歷史最高 41.035
- 量 比 1.11
- 振 幅 0.07%
- 歷史最低 23.4342
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the monotherapy arm of its ABOYA-119 Phase 1/2a study for patients with advanced solid tumors. The company is pausing further enrollment in monotherapy arms to focus on strategic high-value combinations, such as DNA-damaging agents and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor ef...
10-15 12:00
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
Apogee Therapeutics announced that data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis has been accepted for a late-breaker oral presentation at EADV Congress 2025 in Paris. The company will also present multiple posters highlighting APG777’s best-in-class potential and its combination strategy with APG990. APG777 met primary and secondary endpoints in the APEX trial, showing strong efficacy and a favorable tolerab...
09-11 11:30
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Apogee Therapeutics reported positive 16-week Phase 2 Part A data for APG777, a potentially best-in-class anti-IL-13 antibody for moderate-to-severe atopic dermatitis (AD). The drug met all primary and key secondary endpoints, demonstrating significant efficacy and reduced injection burden for patients, potentially requiring 2-4 injections per year versus 26 for current treatments. Part B of the APEX trial is on track for a mid-2026 readout, with...
08-11 11:00
